Glycorex says Transfusion study shows Glycosorb ABO cuts platelet anti-A/B titers with about 4%-5% cell loss

• Glycorex Transplantation highlighted an independent study published in Transfusion validating its Glycosorb ABO device for platelet preparation.
• Results have already been presented via publication, not flagged for a future conference release.
• The study found the technology lowered problematic blood-group antibodies to safer levels while largely preserving platelet yield.
• Data support production of more flexible “universal” low-titer platelets, potentially easing shortages and reducing transfusion-reaction risk.
• Glycorex positioned the publication as external validation that could expand use of its immunoadsorption platform in transfusion markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glycorex Transplantation AB published the original content used to generate this news brief via Cision (Ref. ID: 202609300900BITN____UKPR__EN_20260930-BIT-7346-0) on September 30, 2026, and is solely responsible for the information contained therein.